SRZN News and Press, Surrozen Inc. From 02/05/24

2024-02-05 03:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Announces strategic prioritization of clinical programs to focus on development of SZN-043 for Alcohol-Associated Hepatitis SZN-043 - Completed enrollment for the Phase 1a clinical trial in chronic liver disease patients and healthy volunteers - Expect to announce Phase 1a safety and ...

2023-11-09 08:42:21 ET More on Surrozen Seeking Alpha’s Quant Rating on Surrozen Historical earnings data for Surrozen Financial information for Surrozen For further details see: Surrozen GAAP EPS of -$0.34 misses by $0.03

Surrozen Inc. (SRZN) is expected to report $-0.28 for Q3 2023

Expect to announce data from SZN-043 Phase 1a clinical trial in patients with chronic liver disease and in healthy volunteers in Q1 2024 Expect to announce data from SZN-1326 Phase 1a clinical trial in healthy volunteers in Q1 2024 Initiating Phase 1b studies in 2024 for SZN-043...

2023-08-10 14:32:01 ET Surrozen press release ( NASDAQ: SRZN ): Q2 GAAP EPS of -$0.31 Cash, cash equivalents and marketable securities for the second quarter ended June 30, 2023 were $53.4 million, compared to $61.7 million as of March 31, 2023. For further detai...

SZN-043 Phase 1a clinical trial in patients with chronic liver disease and in healthy volunteers continues to enroll with safety data expected by the end of 2023 SZN-1326 Phase 1a clinical trial in healthy volunteers continues to enroll with safety data expected by the end of 2023 ...

In a preclinical model of ischemic stroke, systemic delivery of a selective Fzd4 Wnt antibody strongly reduced blood-brain-barrier leakage, death of surrounding brain tissue, tissue swelling, while improving neurologic score Results highlight potential of selective Fzd4 Wnt antibody for cen...

2023-05-11 10:44:05 ET Surrozen press release ( NASDAQ: SRZN ): Q1 GAAP EPS of -$0.48 misses by $0.07 . Cash Position: Cash, cash equivalents and marketable securities for the first quarter ended March 31, 2023 were $61.7 million, compared to $75.8 million as of Dece...

Enrollment ongoing in SZN-043 Phase 1a clinical trial in people with chronic liver disease and in healthy volunteers with safety data expected by the end of 2023 Enrollment ongoing in SZN-1326 Phase 1a clinical trial in healthy volunteers with safety data expected by the end of 2023 ...